Dolutegravir (Tivicay®), an integrase inhibitor, was licensed in America a few months ago and is awaiting a European marketing authorisation. Based on information given in the US Prescribing Information (and other metabolic/elimination data), interactions with dolutegravir and comedications have now been added to web and app versions of the charts. Revisions may be required once the European Summary of Product Characteristics is available.
The printable versions of the charts and the treatment selectors will be updated in the next few weeks.
